Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

Affiliations

• ¹ Departments of Investigational Cancer Therapeutics.
• ² Departments of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston.
• ³ Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City.
• ⁴ Departments of Investigational Cancer Therapeutics; Early-Phase Drug Development, Sarah Cannon Research Institute, Nashville, USA. Electronic address: Vivek.Subbiah@scri.com.